Pericoital Oral Contraception With Levonorgestrel

Pericoital Oral Contraception With Levonorgestrel: A Prospective, Open-Label, Single Arm, Multicenter Study to Evaluate Efficacy, Safety and Acceptability

A prospective, open-label, single arm, multicenter study to evaluate efficacy, safety and acceptability of pericoital oral contraception with levonorgestrel

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Drug: levonorgestrel

Detailed Description

This is a prospective, open-label, single arm, multicenter study to evaluate efficacy, safety and acceptability of pericoital oral contraception with levonorgestrel (LNG). The objectives of the study as stated in the study protocol are as follows:

• To evaluate the efficacy of the study regimen among women who have sex 1-4 days a month and who are relying on the study regimen as their primary method of contraception
• To evaluate the safety of this regimen, with particular emphasis on its effects on vaginal bleeding patterns and anemia
• To evaluate the acceptability of the regimen The study will enroll fertile women of reproductive age who have sex up to 6 days a month, are at low risk for sexually transmitted infections (STIs), have no contraindications to progestin-only oral contraceptives,have no serious contraindications to pregnancy, and are willing to use an investigational method of contraception as their only contraceptive method for 6.5 months (each tablet contains 0.75 mg LNG to be used after every sex act).

• Study Type: Interventional
• Enrollment (Actual): 72
• Phase: Phase 3

Contacts and Locations

Study Locations

• Brazil
  • Campinas, Brazil
    • CEMICAMP
• United States
  • Colorado
    • Denver, Colorado, United States, 80232
      • Planned Parenthood of the Rocky Mountains
  • Texas
    • Houston, Texas, United States, 77004
      • Planned Parenthood Gulf Coast, Inc.
  • Utah
    • Salt Lake City, Utah, United States, 84102
      • Planned Parenthood Association of Utah

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: No older than 45 years (Child, Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

Each woman enrolled in the trial must meet the following inclusion criteria:

• Competent to provide informed consent to participate in the trial and has done so.
• At least the minimum age is 18 to 45 years old.
• Had sex 1 to 4 days in past month and expects to continue at that frequency for the next 6.5 months.

• At low risk for sexually transmitted infection (STI), operationally meaning that neither she nor her partner to her knowledge has had any of the following:

  • More than one sexual partner currently or any expectation of having more than one sexual partner in the next 6.5 months
  • Diagnosis of human immunodeficiency virus (HIV) infection, hepatitis B or hepatitis C
  • Treatment for a STI within the past 6 months, excluding recurrent genital herpes or condyloma
  • Sharing of illicit injection drug equipment ever in the past.
• Willing to use the study regimen as her only contraceptive method for the next 6.5 months (except that she may also use condoms if needed for protection from STIs).
• Wants to avoid pregnancy for at least the next 6.5 months.
• Willing to accept an uncertain risk of pregnancy during the study.
• Gives correct answers to the informed consent quiz.
• Willing and able to follow all study requirements.

Exclusion Criteria:

To be eligible for enrollment, a woman must not meet any of the following exclusion criteria:

• Pregnant as verified by a pregnancy test at enrollment.

• Has an indication of current subfecundity, specifically:

  • Her last pregnancy ended within the last 8 weeks, or she has had fewer than two menstrual periods since resolution of last pregnancy
  • She has not had normal monthly menses for the past 2 months
  • She is currently breastfeeding
  • She has used any hormonal contraceptive other than emergency contraceptive pills since the onset of her last menstrual period
  • Has received an injection of a long term injectable contraceptive in the last 9 months
  • Currently has an intrauterine device
  • Has had a sterilization procedure or ectopic pregnancy
  • Has been diagnosed by a clinician as having a fertility problem
  • Her partner has had a sterilization procedure or infertility diagnosis, to her knowledge.

• She currently has known contraindications to progestin-only pills, specifically including the following conditions:

  • Unexplained abnormal vaginal bleeding
  • Deep venous thrombosis or pulmonary embolus
  • Active viral hepatitis
  • Decompensated cirrhosis
  • Liver tumor
  • History of breast cancer within the past 5 years.
• Has a breast mass on examination.
• Has a personal or family history suggestive of predisposition to thrombosis.
• Has a serious contraindication to pregnancy (medical condition or use of chronic medication such as isotretinoin or thalidomide).
• Taking drugs that are known to interact with progestins (such as rifampicin or anticonvulsant medications).
• Has previously participated in this study.
• Currently participating in another medical research study.
• The site investigator or designee perceives another reason to exclude her from the trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Levonorgestrel; 0.75 mg of levonorgestrel within 24 hours of sex	Drug: levonorgestrel; oral contraceptive pills

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Efficacy: the Pearl Index (Number of Pregnancies Per 100 Woman-years) in the Primary Evaluable Population (18-35)	Participants were followed for 6.5 months.Pearl Index in the 18-35 year population was collected excluding months in which barrier methods, condoms, or emergency contraception were used unless the subject conceived	6.5 months
Participant Report of Adverse Events.	Safety data includes data from each subject up to two weeks after her last use of the study tablets as well as all events deemed related to study product, regardless of date last tablet was taken	6.5 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Acceptability Based on Bleeding Patterns Reported	Number of participants who reported bleeding patterns were acceptable and would therefore use Levonorgestrel	6.5 months

Collaborators and Investigators

• Sponsor: FHI 360
• Investigators: Principal Investigator: Vera Halpern, MD, FHI 360

Publications and helpful links

General Publications

• Taylor DJ, Lendvay A, Halpern V, Bahamondes LG, Fine PM, Ginde SY, Wheeless A, Raymond EG. A single-arm study to evaluate the efficacy, safety and acceptability of pericoital oral contraception with levonorgestrel. Contraception. 2014 Mar;89(3):215-21. doi: 10.1016/j.contraception.2013.11.013. Epub 2013 Nov 26.

Study record dates

Study Major Dates

• Study Start: January 1, 2010
• Primary Completion (Actual): November 1, 2010
• Study Completion (Actual): November 1, 2010

Study Registration Dates

• First Submitted: June 10, 2009
• First Submitted That Met QC Criteria: June 16, 2009
• First Posted (Estimate): June 17, 2009

Study Record Updates

• Last Update Posted (Estimate): October 29, 2013
• Last Update Submitted That Met QC Criteria: August 22, 2013
• Last Verified: August 1, 2013

More Information

Terms related to this study

• Keywords: Contraception
• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Contraceptive Agents, Hormonal; Contraceptive Agents; Reproductive Control Agents; Contraceptives, Oral; Contraceptive Agents, Female; Contraceptives, Oral, Synthetic; Levonorgestrel
• Other Study ID Numbers: 10139 (Other Identifier: CTEP)